Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Benefits Most From EMA-FDA Pediatrics 'Cluster' Informal Advice

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and EMA staffers talk monthly on topics related to pediatric uses, resulting in 15 non-binding joint commentaries.

Advertisement

Related Content

Parallel EMA-FDA Pediatric Advice On The Cards For Companies
EMA Pilot For Early Advice On Pediatric Research Finally Gets Going
Priority Review Vouchers Keep Coming, But Expiration Deadline Looms
Pediatric Written Requests Maintain Societal Value of BPCA Exclusivity, AAP Argues
EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development

Topics

Advertisement
UsernamePublicRestriction

Register

PS077897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel